predictoroverall survivalhormonal therapyпрогностический факторобщая выживаемостьгормональная терапия1.1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 году. М., 2009; с. 57.Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 году. М., 2009; с. 57.2.2. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М., 1999.Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М., 1999.3.3. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.4.4. Citrin D.L., Resnick M.I., Guinan P. et al. A comparison of Zoladex results of a randomised, multicenter trial. Prostate 1991;18(2):139–46.Citrin D.L., Resnick M.I., Guinan P. et al. A comparison of Zoladex results of a randomised, multicenter trial. Prostate 1991;18(2):139–46.5.5. The Leuprolide Study Group. N Engl J Med 1984;311(20):1281–6.The Leuprolide Study Group. N Engl J Med 1984;311(20):1281–6.6.6. Denis L., Murphy G.P. Overview of phase III trials on combined androgenic treatment in patients treated with metastatic prostate cancer. Cancer 1993;72(Suppl 12):3888–95.Denis L., Murphy G.P. Overview of phase III trials on combined androgenic treatment in patients treated with metastatic prostate cancer. Cancer 1993;72(Suppl 12):3888–95.7.7. Halabi Susan, Nicholas J. Vogelzang, Alice B. Kornblith et al. Small pain predicts overall survival in men with metastatic castrationrefractory prostate cancer. J Clin Oncol 2008; 26(15):2544–9.Halabi Susan, Nicholas J. Vogelzang, Alice B. Kornblith et al. Small pain predicts overall survival in men with metastatic castrationrefractory prostate cancer. J Clin Oncol 2008; 26(15):2544–9.8.8. Schröder F.H. Management of locally advanced prostate cancer. Staging, natural history, and results of radical surgery. World J Urol 2000;18(3):194–203.Schröder F.H. Management of locally advanced prostate cancer. Staging, natural history, and results of radical surgery. World J Urol 2000;18(3):194–203.9.9. Matzkin H., Perito P.E., Soloway M.S. Prognostic factors in metastatic prostate cancer. Cancer 1993;72(12 Suppl):3788–92.Matzkin H., Perito P.E., Soloway M.S. Prognostic factors in metastatic prostate cancer. Cancer 1993;72(12 Suppl):3788–92.10.10. Matzkin H., Soloway M.S., Schellhammer P.F. et al. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen. Cancer 1993;72(4):1286–90.Matzkin H., Soloway M.S., Schellhammer P.F. et al. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen. Cancer 1993;72(4):1286–90.11.11. Nayyar R., Sharma N., Gupta N.P. Prognostic factors affecting progression and survival in metastatic prostate cancer. Urol Int 2010;84(2):159–63.Nayyar R., Sharma N., Gupta N.P. Prognostic factors affecting progression and survival in metastatic prostate cancer. Urol Int 2010;84(2):159–63.12.12. Cooperberg M.R., Hinotsu S., Namiki M. et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009;27(26):4306–13.Cooperberg M.R., Hinotsu S., Namiki M. et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009;27(26):4306–13.13.13. Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17(3):292–306.Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17(3):292–306.14.14. Shurbaji M.S., Kalbfleisch J.H., Thurmond T.S. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995;26:106–9.Shurbaji M.S., Kalbfleisch J.H., Thurmond T.S. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995;26:106–9.15.15. Dominique S., Ravery V. Preoperative imaging studies: is there any necessity? EAU Update Series 2005;3:72–6.Dominique S., Ravery V. Preoperative imaging studies: is there any necessity? EAU Update Series 2005;3:72–6.16.16. Soloway M.S. The importance of prognostic factors in advanced prostate cancer.Cancer 1990;66(5 Suppl):1017–21.Soloway M.S. The importance of prognostic factors in advanced prostate cancer.Cancer 1990;66(5 Suppl):1017–21.17.17. Hussain M., Tangen C.M., Higano C. et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984–90.Hussain M., Tangen C.M., Higano C. et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984–90.18.18. Akaza H., Hinotsu S., Usami M. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer. Long-Term Follow-Up of a Phase 3, DoubleBlind, Randomized Study for Survival. Cancer 2009;115:3437–45.Akaza H., Hinotsu S., Usami M. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer. Long-Term Follow-Up of a Phase 3, DoubleBlind, Randomized Study for Survival. Cancer 2009;115:3437–45.19.19. Hori S., Jabbar T., Kachroo N. et al. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 2010. [Epub ahead of print].Hori S., Jabbar T., Kachroo N. et al. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 2010. [Epub ahead of print].